Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Oct 2000
Clinical TrialA phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Docetaxel is an active agent used in the treatment of non-small cell lung cancer (NSCLC). ⋯ Docetaxel is active and has an acceptable toxicity profile, in both first- and second-line treatments, in Chinese patients with inoperable NSCLC.
-
Jpn. J. Clin. Oncol. · Dec 1999
Clinical TrialEffect of nebulized morphine in cancer patients with dyspnea: a pilot study.
It is known that opioids may decrease subjective dyspnea. The recent finding that opioid binding sites are present in the peripheral bronchus supports the possibility of a local action of opioids. However, the clinical benefit of nebulized morphine is controversial. The purpose of this study was to confirm the feasibility of nebulized morphine and to evaluate its clinical benefits. ⋯ Our preliminary data confirmed the feasibility of nebulized morphine and suggested its possible clinical benefit for dyspneic patients. A randomized controlled study is warranted to exclude a placebo effect and to compare the clinical benefits of nebulized morphine with those of other methods of treatment.
-
Jpn. J. Clin. Oncol. · Feb 1999
Randomized Controlled Trial Clinical TrialAntiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy.
Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. ⋯ A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.
-
Jpn. J. Clin. Oncol. · Feb 1999
Clinical TrialTropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
We aimed to assess the potency and efficacy of tropisetron, a 5-HT3 receptor antagonist, in the prevention of nausea and emesis observed in the pediatric patient population taking various chemotherapy protocols. ⋯ Tropisetron is safe, effective, easy to use, has no serious side-effects and can be recommended for pediatric patients. The efficacy of tropisetron may be enhanced by the addition of corticosteroids in patients receiving highly emetogenic cancer chemotherapy.